A recent Business Group on Health survey, summarized in reporting by Reuters and Bloomberg, found that about 14% of U.S. employers have either already dropped or plan to drop coverage of GLP-1 weight-loss drugs in 2027. The survey data indicate a meaningful shift in employer benefit design as companies respond to mounting drug costs and increased utilization among covered populations.
Two-thirds of employers responding to the survey reported rising use of GLP-1 medicines among their workforce. Concurrently, the share of employers offering coverage for GLP-1 weight-loss drugs declined from 72% in 2025 to 60% in 2026, reflecting a rapid change in plan coverage within a short period.
According to the material cited in the article, pharmacy costs represented 25% of employer health-care spending. Employers projected a 12% increase in pharmacy spending for 2027, the same rate anticipated the prior year. The combination of elevated utilization of GLP-1 therapies and broader prescription cost pressures appears to be a central factor driving employer decisions about benefit coverage.
The article connects rising utilization of GLP-1 medicines to employer concerns about long-term affordability and the sustainability of current benefit structures. The survey cited is the primary source for these employer-level figures.
The article highlights PepsiCo as a named example of a large employer choosing to drop coverage of weight-loss drugs. Bloomberg News reported on PepsiCo’s decision, which the piece uses to illustrate how major employers are responding in practice to the systemic cost pressures described by the survey.
The piece reports that the number of people working in Massachusetts’ biotech sector fell in 2025, marking the first decline since at least 2002. The state’s biopharma workforce decreased by about 3,600 employees in 2025 to a total of 113,503, a 3.1% reduction from 2024. These figures derive from the Massachusetts Biotechnology Council’s annual industry snapshot, as reported by The Boston Globe and referenced in the article.
The article attributes the workforce contraction in Massachusetts’ biotech sector to a combination of industry headwinds and uncertainty about federal funding for scientific research. Those factors are cited broadly as contributing to employer and industry decisions that led to net workforce reductions in the state during 2025. Specific programmatic or policy changes, employer-level layoffs, or company-level data were not detailed in the provided content.
This Pharmalittle/Pharmalot column is authored by Ed Silverman and indicates that parts of the full story are exclusive to STAT+ subscribers; access to the remainder of the article requires a subscription or login. Notably, although the headline references a GSK shingles shot, the supplied body text does not include any reporting, trial results, regulatory actions, or other details about a GSK shingles vaccine. Those specifics were not present in the source material provided and therefore are not summarized here.
In sum, the provided article content centers on two primary items: shifting employer coverage of GLP-1 weight-loss medicines amid rising utilization and pharmacy spending, and a measurable decline in Massachusetts’ biotech employment in 2025 as reported by the Massachusetts Biotechnology Council. The piece cites Reuters, Bloomberg, and The Boston Globe as sources for those points. The article also makes clear that additional analysis and details are available only to STAT+ subscribers; any further claims or data beyond what is summarized here were not reported in the supplied text.
If you would like, I can: compile the original source links cited in the article, extract the Business Group on Health survey PDF referenced, or summarize the Massachusetts Biotechnology Council industry snapshot directly — but I will only summarize documents you provide or which are present in the source text.